Drug intelligence / Profile preview

SIM0721

Development stage: Preclinical
Lead developer: Simcere Pharmaceutical Group
Administration: Intravenous, Subcutaneous

Overview

SIM0721 is an investigational drug candidate being developed by Jiangsu Xiansheng Re Ming Pharmaceutical (a subsidiary of Simcere Pharmaceutical Group) for the treatment of autoimmune diseases. While specific details regarding its biological target and mechanism of action have not been widely publicized in current clinical pipelines, it is part of Simcere's expanding portfolio in the autoimmune therapeutic area, which includes other novel modalities such as bispecific antibodies and PROTACs. The drug is currently in the early stages of development, with a global development strategy aimed at addressing unmet clinical needs in inflammatory and autoimmune conditions.

Beyond the preview

Go deeper on SIM0721.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIM0721.

Explore the full profile